Active Biotech Yönetim

Yönetim kriter kontrolleri 4/4

Active Biotech CEO'su Helen Tuvesson, Jul2017 tarihinde atandı, in görev süresi 7.33 yıldır. in toplam yıllık tazminatı SEK 4.05M olup, şirket hissesi ve opsiyonları dahil olmak üzere 56% maaş ve 44% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.031% ine doğrudan sahiptir ve bu hisseler € 8.39K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.3 yıl ve 5.5 yıldır.

Anahtar bilgiler

Helen Tuvesson

İcra Kurulu Başkanı

SEK 4.0m

Toplam tazminat

CEO maaş yüzdesi	56.0%
CEO görev süresi	7.3yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	7.3yrs
Yönetim Kurulu ortalama görev süresi	5.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Helen Tuvesson'un ücretlendirmesi Active Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-SEK 42m
Jun 30 2024	n/a	n/a	-SEK 44m
Mar 31 2024	n/a	n/a	-SEK 45m
Dec 31 2023	SEK 4m	SEK 2m	-SEK 46m
Sep 30 2023	n/a	n/a	-SEK 48m
Jun 30 2023	n/a	n/a	-SEK 51m
Mar 31 2023	n/a	n/a	-SEK 54m
Dec 31 2022	SEK 4m	SEK 2m	-SEK 58m
Sep 30 2022	n/a	n/a	-SEK 60m
Jun 30 2022	n/a	n/a	-SEK 57m
Mar 31 2022	n/a	n/a	-SEK 56m
Dec 31 2021	SEK 4m	SEK 2m	-SEK 50m
Sep 30 2021	n/a	n/a	-SEK 38m
Jun 30 2021	n/a	n/a	-SEK 35m
Mar 31 2021	n/a	n/a	-SEK 32m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 32m
Sep 30 2020	n/a	n/a	-SEK 39m
Jun 30 2020	n/a	n/a	-SEK 40m
Mar 31 2020	n/a	n/a	-SEK 36m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 34m
Sep 30 2019	n/a	n/a	-SEK 32m
Jun 30 2019	n/a	n/a	-SEK 31m
Mar 31 2019	n/a	n/a	-SEK 35m
Dec 31 2018	SEK 3m	SEK 1m	-SEK 37m
Sep 30 2018	n/a	n/a	-SEK 88m
Jun 30 2018	n/a	n/a	-SEK 88m
Mar 31 2018	n/a	n/a	-SEK 103m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 109m

Tazminat ve Piyasa: Helen 'ın toplam tazminatı ($USD 366.29K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 471.55K ).

Tazminat ve Kazançlar: Helen 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Helen Tuvesson (62 yo)

7.3yrs

Görev süresi

SEK 4,045,000

Tazminat

Ms. Helen Tuvesson, Ph.D. is President of Active Biotech AB and its Chief Executive Officer since 2017. She serves as Independent Director at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Helen Tuvesson	President & CEO	7.3yrs	SEK 4.05m	0.031% € 8.4k
Hans Kolam	Chief Financial Officer	24.8yrs	Veri yok	0.023% € 6.2k
Erik Vahtola	Chief Medical Officer	2.8yrs	Veri yok	0.011% € 3.0k

7.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: BTPC 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peter Thelin	Independent Director	13.5yrs	SEK 206.00k	Veri yok
Uli Hacksell	Independent Director	5.5yrs	SEK 202.00k	0.0017% € 457.3
Michael Shalmi	Independent Chairman of the Board	5.5yrs	SEK 524.00k	0.049% € 13.1k
Axel Glasmacher	Independent Director	4.5yrs	SEK 203.00k	0.0032% € 869.2
Aleksandar Danilovski	Independent Director	4.5yrs	SEK 207.00k	0.015% € 4.1k

5.5yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BTPC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).

Active Biotech Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Insufficient new directors

Active Biotech's Announces Nomination Committee

High number of new and inexperienced directors

Independent Chairman of the Board recently bought €26k worth of stock

Recent updates

New major risk - Financial position

New major risk - Market cap size

Active Biotech AB (Publ) Reports Intention Inaugural Interocular Concentrations Achieves in A Clinical Bylistribution Study of Laquinimod Eye Drops

No longer forecast to breakeven

Active Biotech Provides Update on the Clinical Phase Ib/IIa Study with Tasquinimod in Relapsed Refractory Multiple Myeloma

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis

Active Biotech AB (publ) Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Active Biotech AB (Publ) Provides Update on the Scheduled Clinical Program for 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Forecast breakeven date pushed back to 2025

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

New minor risk - Profitability

Forecast to breakeven in 2024

Active Biotech AB (publ) Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis

Insufficient new directors

Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma

Active Biotech AB (Publ) Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops

Active Biotech AB (publ) to Report First Half, 2023 Results on Aug 24, 2023

Active Biotech's Announces Nomination Committee

Forecast to breakeven in 2024

Active Biotech AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023

Active Biotech AB (Publ) Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage

Active Biotech AB (publ) announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis

High number of new and inexperienced directors

Active Biotech AB (publ) to Report Q3, 2022 Results on Nov 03, 2022

Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/IIa Study of Tasquinimod in Multiple Myeloma

Active Biotech AB (publ) Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod

Active Biotech AB (publ) Provides Status Update of its Clinical Naptumomab Project

Independent Chairman of the Board recently bought €26k worth of stock

New 90-day high: €0.25

Active Biotech Receive Milestone Payment from Neotx

Active Biotech AB Appoints Elaine Sullivan as A Director

Earnings released

New 90-day high - €0.32

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş